161 completed, 21 terminated, 8 withdrawn, 6 recruiting. 151 Phase 2, 42 Phase 1, 5 Phase 3, 3 Not applicable, 1 Phase 4.
Follow SCRI Development Innovations, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet - TP53 Y220C Mutation, Advanced Solid Tumors | Phase 1 | Recruiting | PMV Pharmaceuticals, Inc | 14 | 2026-02-04 | 2026-08-12 |
| A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) - Colon Cancer, Rectal Cancer | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 60 | 2025-09-29 | 2026-06-12 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2025-08-08 | 2026-06-04 |
| BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) BMS-986489, Durvalumab - Limited Stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | SCRI Development Innovations, LLC | 250 | 2025-03-11 | 2026-09-21 |
| Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib Lorlatinib, Cisplatin or Carboplatin, Pemetrexed - Lung Cancer, Non-small Cell Lung Cancer | Phase 2 | Withdrawn | SCRI Development Innovations, LLC | 2023-11-01 | 2023-12-13 | |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma Teclistamab, Talquetamab, Tocilizumab - Multiple Myeloma | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2023-10-23 | 2026-04-22 |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Tucatinib, Doxil - Breast Cancer | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 36 | 2023-07-24 | 2026-03-20 |
| A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer U3-1402 - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 121 | 2021-05-03 | 2026-05-22 |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma Acalabrutinib - Mantle Cell Lymphoma | Phase 2 | Completed | SCRI Development Innovations, LLC | 15 | 2020-08-07 | 2025-05-13 |
| A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Itacitinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | SCRI Development Innovations, LLC | 15 | 2020-06-05 | 2024-11-06 |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia CPX-351, Quizartinib - Leukemia, Myeloid, Acute | Phase 2 | Terminated | SCRI Development Innovations, LLC | 1 | 2020-06-03 | 2023-12-05 |
| A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests Direct Antigen Tests for COVID-19 - SARS CoV-2 | Not applicable | Completed | E25Bio, Inc. | 200 | 2020-04-24 | 2020-10-19 |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide Nivolumab - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 | Withdrawn | SCRI Development Innovations, LLC | 2020-04-13 | 2023-12-05 | |
| Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Atezolizumab, Standard of Care Chemotherapy, Tiragolumab - Non-Small Cell Lung Cancer, Solid Tumor | Phase 2 | Completed | SCRI Development Innovations, LLC | 46 | 2019-08-30 | 2025-08-27 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors EDP1503, Pembrolizumab - Colorectal Cancer Metastatic, Triple Negative Breast Cancer | Phase 1 | Completed | Evelo Biosciences, Inc. | 69 | 2018-12-19 | 2023-03-24 |
| Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk Nivolumab - Hodgkin Lymphoma | Phase 2 | Completed | SCRI Development Innovations, LLC | 37 | 2018-05-23 | 2023-12-05 |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Lanreotide, Y-90 microspheres - Neuroendocrine Tumors, Gastrointestinal Neoplasms | Phase 2 | Terminated | SCRI Development Innovations, LLC | 6 | 2017-07-28 | 2023-12-05 |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma nab-paclitaxel, Gemcitabine - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Terminated | SCRI Development Innovations, LLC | 3 | 2017-01-12 | 2023-12-05 |
| Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Afatinib, Regorafenib, Cabozantinib - Non-small Cell Lung Carcinoma, Urothelial Carcinoma | Phase 2 | Completed | SCRI Development Innovations, LLC | 100 | 2016-09-28 | 2023-12-05 |
Showing 20 of 197. Sign in to see all of them.
Breast Neoplasms (36) · Lung Neoplasms (23) · Carcinoma, Non-Small-Cell Lung (19) · Multiple Myeloma (12) · Neoplasm Metastasis (11) · Colorectal Neoplasms (10) · Neoplasms (9) · Lymphoma, Non-Hodgkin (8) · Carcinoma, Renal Cell (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Recurrence (7) · Small Cell Lung Carcinoma (7) · Ovarian Neoplasms (6) · Esophageal Neoplasms (5) · Kidney Neoplasms (5)
Carboplatin (37) · Bevacizumab (35) · Paclitaxel (19) · Docetaxel (18) · Gemcitabine (17) · Fluorouracil (15) · Erlotinib Hydrochloride (12) · Topotecan (12) · Oxaliplatin (11) · Everolimus (10) · Rituximab (10) · Sorafenib (10) · Trastuzumab (10) · Irinotecan (9) · Leucovorin (9)
United States (170) · Canada (2) · United Kingdom (2) · Puerto Rico (1) · Spain (1)
John D. Hainsworth, MD (26) · David R. Spigel, MD (11) · Denise A. Yardley, MD (10) · David Spigel, M.D. (8) · John D. Hainsworth, M.D. (8) · Anthony Greco, MD (7) · Johanna Bendell, MD (6) · David R Spigel, M.D. (5) · David R Spigel, MD (5) · Denise A Yardley, M.D. (5) · John D Hainsworth, M.D. (4) · John D Hainsworth, MD (4) · Melissa Johnson, MD (4) · Denise A Yardley, MD (3) · Denise A. Yardley, M.D. (3)
PMID 19901100, PMID 16179100, PMID 16204015, PMID 16877720, PMID 16939953, PMID 17470864, PMID 17553208, PMID 17805064, PMID 17823908, PMID 17922972, PMID 18189296, PMID 18272024, PMID 18543319, PMID 18621625, PMID 18650154, PMID 18952556, PMID 19288572, PMID 19299236, PMID 19525191, PMID 19661042, PMID 19875975, PMID 19933079, PMID 19933081, PMID 19965914, PMID 20158340, PMID 20164695, PMID 20209610, PMID 20210519, PMID 20223728, PMID 20351330, PMID 20368560, PMID 20421819, PMID 20439197, PMID 20497920, PMID 20521352, PMID 20521355, PMID 20564147, PMID 20564157, PMID 20658263, PMID 20690802, PMID 20690806, PMID 21663862, PMID 22947511, PMID 23032625, PMID 23665131, PMID 23969699, PMID 25335932, PMID 25710456, PMID 26327916, PMID 26911408